Sygnature Discovery Limited

Activities: Research & Development

Trending Articles

  1. OINDPs: Nosey about recent developments? OINDPs are a user friendly and efficacious alternative to injectables in several disease areas
  2. Transforming healthcare with patient centricity In this opinion article, John Kytariolos, Head of Clinical and Scientific Affairs at Adragos Pharma, discusses patient-centric dosage forms, their properties and the impact...
  3. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  4. Compact process thermostat for efficient temperature control in the laboratory The temperature control system is designed for the accurate temperature control of small research reactors between -40 to +200 °C
  5. AviadoBio expands presence at Canary Wharf The company has acquired 11,000 sqft of laboratory and office space in Canary Wharf to accommodate the growing team

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Finance

Sygnature Discovery invests £3.75m in compound management to provide cutting-edge hit finding capabilities

Sygnature Discovery has unveiled its latest investment in a state-of-the-art Azenta compound management storage system, which also provides the opportunity to store customer libraries
Drug Delivery

Sygnature acquires CRO NuChem Sciences

This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions
Manufacturing

Sygnature launches in vivo model to profile early-stage anti-inflammatory drugs

The LPS in vivo model supports early-stage anti-inflammatory drug discovery in neuroinflammation, kidney, and systemic inflammation
Research & Development

Accelerating drug discovery with market leading cell line generation

In January 2023, integrated drug discovery company Sygnature Discovery announced the acquisition of SB Drug Discovery, a world-leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications
Finance

Sygnature Discovery acquires Peak Proteins

Peak Proteins’ core technologies include protein expression and purification
Research & Development

Sygnature Discovery appoints Chair

As Chairman, Dr Woler will support Sygnature Discovery’s recruitment efforts, broaden its therapeutic areas and grow its presence in North America
Finance

Sygnature Discovery appoints Chief Financial Officer

"This is a fantastic place to work and home to real scientific innovation, so there are plenty of brilliant opportunities ahead of us."
Subscribe now